Recent Quotes

My Watchlist

Indicators

Currencies

International

Treasuries

Keros Therapeutics, Inc. - common stock (NQ:KROS)

19.17 +0.59 (+3.18%)

Streaming Delayed Price Updated: 3:39 PM EST, Jan 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	327,854
Open	18.87
Bid (Size)	19.16 (100)
Ask (Size)	19.20 (100)
Prev. Close	18.58
Today's Range	18.72 - 19.49
52wk Range	9.120 - 22.55
Shares Outstanding	23,337,862
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Keros Therapeutics Inc (NASDAQ:KROS) Emerges as a High-Growth Momentum Breakout Candidate ↗

December 25, 2025

Keros Therapeutics exemplifies a high-growth momentum strategy, combining explosive revenue growth, perfect technical ratings, and a defined breakout setup for potential entry.

Via Chartmill

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst ↗

June 10, 2025

BofA's Zemansky downgraded Keros to Neutral, citing limited near-term upside, cautious sentiment, and unresolved investor concerns.

Via Benzinga

Performance

YTD	+3.4%	+3.4%
1 Month	-11.0%	-11.0%
3 Month	+18.9%	+18.9%
6 Month	+32.5%	+32.5%
1 Year	+28.7%	+28.7%

More News

Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% ↗

May 29, 2025

Via Benzinga

Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price ↗

April 11, 2025

Via Benzinga

Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan ↗

April 10, 2025

Via Benzinga

Analyst Expectations For Keros Therapeutics's Future ↗

February 27, 2025

Via Benzinga

Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings) ↗

January 17, 2025

Via Benzinga

These stocks are gapping in today's session ↗

April 10, 2025

Via Chartmill

Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed ↗

April 10, 2025

Via Stocktwits

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump ↗

April 10, 2025

Via Benzinga

PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday ↗

April 10, 2025

Via Benzinga

Where Keros Therapeutics Stands With Analysts ↗

December 16, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 10, 2025

Via Benzinga

Forecasting The Future: 7 Analyst Projections For Keros Therapeutics ↗

April 01, 2025

Via Benzinga

KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the Firm

January 24, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS)

January 22, 2025

From Kirby McInerney LLP

Via Business Wire

Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views ↗

January 15, 2025

Via Benzinga

Nasdaq Surges Over 2%; Goldman Sachs Posts Upbeat Q4 Results ↗

January 15, 2025

Via Benzinga

Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes ↗

January 15, 2025

Via Stocktwits

Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - KROS

December 17, 2024

Via ACCESSWIRE

Shareholders that lost money on Keros Therapeutics, Inc.(KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS

December 16, 2024

Via ACCESSWIRE

Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud

December 16, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 12, 2024

Via Benzinga

Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher ↗

December 12, 2024

Via Benzinga

Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook ↗

December 12, 2024

Via Benzinga

Frequently Asked Questions

Is Keros Therapeutics, Inc. - common stock publicly traded?

Yes, Keros Therapeutics, Inc. - common stock is publicly traded.

What exchange does Keros Therapeutics, Inc. - common stock trade on?

Keros Therapeutics, Inc. - common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Keros Therapeutics, Inc. - common stock?

The ticker symbol for Keros Therapeutics, Inc. - common stock is KROS on the Nasdaq Stock Market

What is the current price of Keros Therapeutics, Inc. - common stock?

The current price of Keros Therapeutics, Inc. - common stock is 19.17

When was Keros Therapeutics, Inc. - common stock last traded?

The last trade of Keros Therapeutics, Inc. - common stock was at 01/09/26 03:39 PM ET

What is the market capitalization of Keros Therapeutics, Inc. - common stock?

The market capitalization of Keros Therapeutics, Inc. - common stock is 447.39M

How many shares of Keros Therapeutics, Inc. - common stock are outstanding?

Keros Therapeutics, Inc. - common stock has 447M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.